Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Bortezomib
Drug ID BADD_D00284
Description Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma.[A204083] The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib.[L14180] However, multiple mechanisms may be involved in the anticancer activity of bortezomib.[A204083] Bortezomib was first synthesized in 1995.[A204083] In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE.[A204146] Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.[A214307]
Indications and Usage Bortezomib is indicated for the treatment of adult patients with multiple myeloma or mantle cell lymphoma.[L14177]
Marketing Status approved; investigational
ATC Code L01XG01
DrugBank ID DB00188
KEGG ID D03150
MeSH ID D000069286
PubChem ID 387447
TTD Drug ID D0SH3I
NDC Product Code 62158-0011; 65129-1264; 0409-1703; 70710-1411; 51817-586; 68001-541; 14096-140; 0143-9098; 67184-0530; 71288-118; 72205-183; 63323-821; 12502-5268; 42385-716; 55111-922; 63323-721; 68001-534; 48957-0018; 10019-991; 70225-1102; 50742-484; 70511-161; 47848-031; 54893-0011; 66529-0006; 76055-0027; 82920-006; 0409-1704; 70771-1708; 72266-243; 72266-244; 54245-7004; 62207-972; 67184-0026; 60505-6050; 70511-162; 25021-244; 68001-540; 42973-140; 55150-337; 63020-049; 0409-1700; 70860-225; 62756-982; 68554-0051; 78848-009
UNII 69G8BD63PP
Synonyms Bortezomib | LDP-341 | LDP 341 | LDP341 | PS 341 | 341, PS | PS-341 | PS341 | Velcade
Chemical Information
Molecular Formula C19H25BN4O4
CAS Registry Number 179324-69-7
SMILES B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Musculoskeletal discomfort15.03.04.001--Not Available
Inappropriate antidiuretic hormone secretion14.05.07.001; 05.03.03.0010.000448%Not Available
Injection site swelling12.07.03.018; 08.02.03.0170.001198%Not Available
Type III immune complex mediated reaction10.01.03.023--Not Available
Thermal burn23.03.11.042; 12.05.04.001--
Injection site discomfort12.07.03.019; 08.02.03.0180.000381%Not Available
Cerebral disorder17.02.10.0170.000112%Not Available
Infusion site reaction12.07.05.006; 08.02.05.0050.000381%Not Available
Haemorrhage24.07.01.002--Not Available
Faecaloma07.01.03.004--Not Available
Pulmonary mass22.02.07.0040.000168%Not Available
Erythrosis23.03.03.055; 01.05.01.014--Not Available
Peripheral sensorimotor neuropathy17.09.03.0090.000112%Not Available
Faecalith07.01.03.007--Not Available
Anxiety disorder19.06.01.002--Not Available
Cognitive disorder19.21.02.001; 17.03.03.003--
Major depression19.15.01.0030.000112%Not Available
Injection site nodule12.07.03.034; 23.07.04.009; 08.02.03.0340.000246%Not Available
Toxic skin eruption12.03.01.073; 23.03.05.003; 10.01.01.0080.000168%Not Available
Staphylococcal infection11.02.05.002--Not Available
Metabolic disorder14.11.01.001--Not Available
Troponin I increased13.04.01.005--
Muscle relaxant therapy25.16.01.001--Not Available
Restless legs syndrome17.02.07.008; 15.05.03.012--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Hepatic vein occlusion24.04.07.005; 09.01.06.011--Not Available
Gastrointestinal toxicity12.03.01.019; 07.08.03.0060.000638%Not Available
Ventricular dysfunction02.04.02.005--Not Available
Angiopathy24.03.02.0070.000112%Not Available
Drug resistance08.06.01.0050.001310%Not Available
The 21th Page    First    Pre   21 22 23 24 25    Next   Last    Total 26 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene